Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
63759-3050-01 63759-3050 Pemetrexed disodium Pemetrexed 1000.0 mg/100mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2024 In Use
40051-0607-53 40051-0607 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 1, 2016 In Use
62756-0102-60 62756-0102 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct 1, 2018 Jul 31, 2023 No Longer Used
72485-0213-15 72485-0213 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Sep 4, 2020 In Use
00179-0195-70 00179-0195 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec 2, 2015 Nov 30, 2017 In Use
70436-0106-80 70436-0106 Cyclophosphamide for Injection Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 26, 2025 In Use
66758-0050-01 66758-0050 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jun 29, 2011 In Use
71288-0169-25 71288-0169 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb 28, 2022 In Use
00069-0152-01 00069-0152 Cytarabine Cytarabine 100.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Dec 14, 2011 Dec 31, 2017 No Longer Used
70069-0836-01 70069-0836 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Apr 29, 2025 In Use
64679-0793-01 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 17, 2019 In Use
70121-1238-01 70121-1238 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral May 31, 2018 In Use
40051-0607-12 40051-0607 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 1, 2016 In Use
68382-0245-16 68382-0245 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use
00093-7639-41 00093-7639 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 12, 2013 Jul 31, 2019 In Use
47335-0893-74 47335-0893 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb 13, 2014 In Use
73207-0303-41 73207-0303 Vimseltinib ROMVIMZA 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R Oral Feb 14, 2025 In Use
60505-6279-00 60505-6279 Cisplatin CISplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 13, 2024 In Use
50742-0482-50 50742-0482 fluorouracil FLUOROURACIL 2.5 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec 21, 2019 In Use
00409-0201-26 00409-0201 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sep 9, 2013 Jan 31, 2017 In Use
43975-0308-10 43975-0308 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Mar 20, 2018 Feb 28, 2021 No Longer Used
16714-0857-01 16714-0857 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Jan 8, 2019 In Use
63323-0136-10 63323-0136 Bleomycin Sulfate Bleomycin 15.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous Feb 13, 2009 In Use
00013-2596-91 00013-2596 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb 17, 1997 In Use
69488-0003-01 69488-0003 Lutetium Lu 177 dotatate Lutathera 10.0 mCi/mL Chemotherapy Radiopharmaceutical Somatostatin Analog Intravenous Jan 26, 2018 In Use

Found 11564 results — Export these results